Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Sanofi

Regeneron Pharmaceuticals, Inc. REGN reported third-quarter 2025 adjusted earnings per share (EPS) of $11.83, which comfortably beat the Zacks Consensus Estimate of $9.44. However, the bottom line was down 5% from $12.46 recorded in the year-ago quarter, primarily due to higher expenses.
Total revenues grew 1% year over year to $3.7 billion due to higher sales of Eylea HD and increased Dupixent profits. Revenues also beat the Zacks Consensus Estimate of $3.6 billion.
Shares are trading up in response to the better-than-expected quarterly results.
Regeneron’s shares have lost 17.8% year to date against the industry’s growth of 10.3%.
Image Source: Zacks Investment Research
Eylea HD, Dupiexent Power REGN’s Q3 Results
Lead drug, Eylea, is approved for various ophthalmology indications (neovascular age-related macular degeneration, diabetic macular edema and macular edema, among others).
Eylea’s sales in the United States plunged 41% year over year to $681 million, primarily due to increased competition from other drugs like Roche’s RHHBY Vabysmo, loss in market share to compounded bevacizumab due to patient affordability constraints and transition of patients to higher doses of the drug (Eylea HD).
Nonetheless, Eylea sales in the United States fell short of the Zacks Consensus Estimate of $686 million.
Please note that Regeneron co-developed Eylea with the HealthCare unit of Bayer AG BAYRY. Regeneron records net product sales of Eylea and Eylea HD in the United States and Bayer does the same outside the country. The company records its share of profits in connection with Eylea and Eylea HD sales outside the United States within collaboration revenues.
In August 2023, the FDA approved Eylea HD (higher dose of Eylea) for the treatment of patients with wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy.
Eylea HD generated revenues of $431 million in the United States, up 10% year over year, due to higher sales volumes driven by increased demand. Eylea HD sales beat the Zacks Consensus Estimate of $414 million.
Total revenues include collaboration revenues of $2 billion from Sanofi SNY and Bayer. The figure increased 18.6% from that recorded in the year-ago quarter. Total collaboration revenues beat the Zacks Consensus Estimate of $1.8 billion.
Sanofi’s collaboration revenues increased 28% to $1.6 billion, driven by profits associated with higher Dupixent sales. The figure beat the Zacks Consensus Estimate of $1.5 billion. We note that Sanofi records global net product sales of Dupixent and Kevzara, while Regeneron records its share of profits/losses in connection with the global sales of both drugs within collaboration revenues. Dupixent’s sales increased 27% year over year to $4.86 billion.
Bayer’s collaboration revenues totaled $345 million, down 12% year over year.
Regeneron records net product sales of Praluent in the United States and Sanofi does the same outside the country. SNY pays REGN a royalty on such sales. Regeneron records global net product sales of Libtayo and pays Sanofi a royalty on such sales.
Total Libtayo sales were $365.2 million, up 27% year over year. The figure, however, missed the Zacks Consensus Estimate of $370 million.
Praluent’s net sales in the United States were $67.7 million. Kevzara recorded global sales of $154 million, up 28% from the year-ago quarter’s level.
Gross margin on net product sales decreased to 86% from 89% due to ongoing investments to support the manufacturing operations.
Adjusted R&D expenses increased 18% year over year to $1.3 billion due to the advancement of the company's pipeline. Adjusted SG&A expenses decreased 12% to $541 million.
In February 2025, the board of directors authorized a new share repurchase program to repurchase up to an additional $3.0 billion of the common stock. During the second quarter of 2025, REGN repurchased shares for $663 million. As of June 30, 2025, approximately $2.156 billion remained available for share repurchases.
REGN’s Key Pipeline and Regulatory Updates
The European Medicines Agency’s (“EMA”) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of Dupixent in the European Union (EU) for the treatment of chronic spontaneous urticaria (CSU) in adults and adolescents aged 12 years and older who remain symptomatic despite antihistamine treatment.
A decision from the European Commission is expected in the coming months.
The FDA issued a complete response letter (CRL) for the pre-filled syringe supplemental biologics license application (sBLA) seeking approval of Eylea HD. The sole approvability issue cited in the CRL relates to unresolved inspection findings at Catalent.
REGN is planning to submit an application to include a new pre-filled syringe manufacturing filler in the Eylea HD BLA by January 2026.
The FDA recently approved the label expansion of PD-1 inhibitor Libtayo as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma (“CSCC”) at high risk of recurrence after surgery and radiation.
The EMA's CHMP also adopted a positive opinion on Libtayo for the adjuvant treatment of CSCC.
REGN also announced that the primary and key secondary endpoints were met in a phase III study of cemdisiran (siRNA therapy), as both a monotherapy and in combination with pozelimab (C5 antibody), in adults with generalized myasthenia gravis. A regulatory submission for cemdisiran monotherapy is planned for the first quarter of 2026 in the United States pending discussions with the FDA.
Our Take on REGN’s Q3 Performance
Regeneron's performance in the third quarter was encouraging as revenues grew despite declining sales of its lead drug Eylea.
Regeneron Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Regeneron Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Regeneron Pharmaceuticals, Inc. Quote
Eylea sales continue to be on the downslide due to competition from Vabysmo. We note that Vabysmo's uptake has been outstanding. Roche designed Vabysmo to block pathways involving Ang-2 and VEGF-A.
Nonetheless, REGN is looking to strengthen its oncology portfolio to diversify its revenue stream.
The company’s oncology franchise received a boost with the recent FDA approval of a label expansion of Libtayo.
The regulatory body had earlier approved linvoseltamab-gcpt for the treatment of relapsed or refractory (R/R) multiple myeloma (MM). The drug was granted accelerated approval by the FDA under the brand name Lynozyfic. It is also approved in the European Union (EU) to treat adults with R/R MM after at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.
The EU approval of Ordspono (odronextamab) for treating adult patients with R/R follicular lymphoma or R/R diffuse large B-cell lymphoma after two or more lines of systemic therapy has also strengthened its oncology franchise.
Zacks Rank
Regeneron currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Quantum Computing Stocks Set To Soar
Artificial intelligence has already reshaped the investment landscape, and its convergence with quantum computing could lead to the most significant wealth-building opportunities of our time.
Today, you have a chance to position your portfolio at the forefront of this technological revolution. In our urgent special report, Beyond AI: The Quantum Leap in Computing Power, you'll discover the little-known stocks we believe will win the quantum computing race and deliver massive gains to early investors.
Access the Report Free Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

REGN Stock Up on Q3 Earnings Beat, Eylea HD Sales Increase

(RTTNews) - Medidata, a Dassault Systèmes brand and a leading provider of clinical trial solutions for the life sciences industry, announced an extension of its strategic partnership with Sanofi. Under the renewed agreement, Sanofi will adopt Medidata's Patient, Data, and Study Experiences to further its mission of accelerating innovation in clinical studies, bringing new therapies to market faster, and improving global health outcomes.
The Medidata Experiences offer AI-driven, platform-based solutions that streamline clinical workflows, replacing fragmented and standalone tools commonly used in the industry. By integrating these capabilities with Sanofi's pharmaceutical expertise, the collaboration aims to enhance the precision and impact of clinical trials while reducing operational silos, costs, and delays.
As part of the expanded partnership, Sanofi will leverage Medidata's leadership in decentralized clinical trials. Medidata will provide comprehensive consulting and end-to-end operational support to help execute more agile and patient-centric studies.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Medidata And Sanofi Expand Collaboration To Advance Clinical Research Innovation

In trading on Friday, shares of Sanofi (Symbol: SNY) crossed above their 200 day moving average of $51.00, changing hands as high as $52.20 per share. Sanofi shares are currently trading up about 4.7% on the day. The chart below shows the one year performance of SNY shares, versus its 200 day moving average:
Looking at the chart above, SNY's low point in its 52 week range is $44.6168 per share, with $60.115 as the 52 week high point — that compares with a last trade of $51.64.
Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average »
Also see:
HEI Average Annual Return
Top Ten Hedge Funds Holding PYPL
Delta Air Lines Historical Earnings
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Sanofi Breaks Above 200-Day Moving Average - Bullish for SNY

Sanofi SNY reported third-quarter 2025 adjusted earnings of $1.70 per American depositary share, which beat the Zacks Consensus Estimate of $1.60. Earnings of €2.91 per share rose 7% on a reported basis and 13.2% on a constant currency rate (“CER”) basis, driven by cost control and operational efficiency
Net sales rose 2.3% on a reported basis to $14.52 billion (€12.43 billion). Sales rose 7% on a CER basis. Sales slightly beat the Zacks Consensus Estimate of $14.46 billion.
Sales rose 11.1% at CER in the United States, 1.9% in the Rest of the World (including China, Japan, Brazil and Russia) and 2.8% in Europe.
All growth rates mentioned below are on a year-on-year basis and at CER.
SNY’s Dupixent Continues to Outperform
In Immunology, Dupixent generated sales of €4.2 billion in the quarter, up 26.2% year over year, driven by strong prescription trends across all approved indications and geographies. Dupixent sales beat our model estimate of €4.03 billion.
Dupixent is approved for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, prurigo nodularis and chronic obstructive pulmonary disease (COPD) in the United States as well as several other countries. Dupixent was approved for its seventh indication, chronic spontaneous urticaria, in April 2025 and for its eighth indication, bullous pemphigoid, in June 2025, in the United States.
Sales of the drug in the United States rose 27.9%. Dupixent sales rose 20.9% in Europe and 21.7% in the Rest of the World.
Sanofi markets Dupixent in partnership with Regeneron REGN. While sales are recorded by Sanofi, Regeneron records its share of profits/losses in connection with global sales of Dupixent.
SNY’s Rare Disease Drugs’ Performance
Among Sanofi’s rare disease drugs, rare blood disorder drug Altuviiio, a once-weekly new class of factor VIII therapy for hemophilia A, recorded sales of €294 million in the third quarter, up 81.4% year over year, mainly driven by patient switches in the U.S. hemophilia A market and launch in Japan and Taiwan. As much as 84% of Altuviiio’s sales were in the United States.
Among the rare disease drugs in the Pompe franchise, Nexviazyme/Nexviadzyme recorded sales of €200 million, up 27.6% year over year, mainly driven by strong sales growth in Europe. Myozyme sales declined 25% year over year to €122 million due to patients switching to Nexviazyme. Fabrazyme sales were €242 million, down 0.4% year over year. In the Gaucher franchise, Cerezyme sales rose 0.6% year over year to €161 million.
Cablivi recorded sales of €66 million, up 9.5% year over year, driven by patient growth in the United States and Europe.
Among the rare blood disorder drugs, Eloctate sales declined 14.6% to €77 million in the quarter due to patients switching to the new drug Altuviiio.
Xenpozyme recorded sales of €57 million in the quarter, up 43.9% year over year.
New drug Qfitlia (fitusiran), which was approved by the FDA in March for treating hemophilia A and B, generated €4 million in sales compared to €1 million in the previous quarter.
Wayrilz (rilzabrutinib), which was approved for treating immune thrombocytopenia in the United States in August, generated €1 million in sales in the third quarter.
All sales of Qfitlia and Wayrilz were in the United States in the third quarter, as the drugs are not yet approved in Europe.
Ayvakit, added from the mid-July acquisition of Blueprint Medicines, recorded sales of €137 million.
SNY’s Neurology, Oncology & Other Drugs
In neurology medicines, Aubagio sales declined 44.6% year over year to €49 million due to loss of exclusivity.
In Oncology, Sarclisa sales rose 41.2% year over year to €155 million, driven by market share gains globally and increased use in earlier lines of treatment.
In Others, Toujeo recorded sales of €321.0 million, up 9.2% year over year, driven mainly by higher sales in Rest of World. Lantus sales rose 6.7% to €438 million. Rezurock recorded sales of €114 million, down 6.9% year over year. Tzield sales were €18 million in the quarter, up 26.7% year over year.
Plavix sales rose 1.3% to €223 million. Lovenox sales decreased 14.6% to €196 million.
SNY’s Vaccine Sales Decline
Total vaccine sales declined 7.8% to €3.36 billion, mainly due to lower sales of flu vaccines, which were partially offset by higher sales of Sanofi and partner AstraZeneca’s AZN respiratory syncytial virus or RSV antibody, Beyfortus. Vaccine sales missed our estimate of €3.47 billion.
Sales of flu vaccines declined 16.8% year over year to €1.53 billion due to increased price competition and a lower vaccination rate. Sales of Polio/Pertussis/Hib (PPH) vaccines declined 12.2% year over year to €642 million. Sales of meningitis, travel and other endemic vaccines declined 1.9% year over year to €451 million in the quarter.
AstraZeneca-partnered Beyfortus recorded sales of €739 million in the quarter, up 19.8% year over year, driven by the geographical roll-out of infant protection in Europe and the Rest of the World.
SNY Maintains 2025 Guidance
Sanofi maintained its previously issued sales and earnings growth expectations for 2025.
Sanofi expects sales to rise by a high single-digit percentage at CER. Sanofi expects earnings to rebound strongly in 2025 with an expectation of a low double-digit percentage growth at CER (before stock buyback).
In January, Sanofi announced a €5 billion ($5.2 billion) buyback program for 2025. Sanofi has already repurchased 86.1% of €5 billion and plans to complete the program this year.
Our Take on SNY’s Q3 Results
Sanofi’s third-quarter results were strong as it beat estimates for earnings as well as sales. Higher sales of Dupixent and contributions from new products like Altuviiio and Ayvakit drove top-line growth despite lower sales of vaccines. Dupixent continues to be the key top-line driver with global sales rising above €4 billion in a quarter for the first time. Sales of its newly launched drugs and vaccines rose 40.8% in the quarter. Sanofi maintained its growth expectations for 2025 and expects continued profitable growth in 2026.
Sanofi’s shares were up around 2% in pre-market trading in response to the strong quarterly results.
Sanofi’s stock has risen 2.7% so far this year compared with the industry’s increase of 5.5%.
Image Source: Zacks Investment Research
Several new drugs launched in the past couple of years have become significant contributors to Sanofi's accelerated top-line growth profile. Sanofi expects three potential new drug launches this year, with Qfitlia and Wayrilz already launched. A regulatory application seeking approval for tolebrutinib for non-relapsing secondary progressive multiple sclerosis is under review in the United States, with an FDA decision expected later this year.
Sanofi has also been active on the M&A front. This year, it acquired Blueprint Medicines, which has expanded its presence in rare immunological diseases and Vigil Neuroscience, which expanded its early-stage pipeline in neurology with VG-3927, a novel, oral, small-molecule TREM2 agonist targeting Alzheimer’s disease.
In April 2025, Sanofi closed its previously announced transaction to sell a 50% controlling stake of its Consumer Healthcare business, Opella, to private equity firm CD&R. Sanofi retains a 48.2% stake in Opella.
SNY’s Zacks Rank
Sanofi currently has a Zacks Rank #3 (Hold).
Sanofi Price and Consensus
A better-ranked large drugmaker is Bayer BAYRY, which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Bayer’s shares have risen 63.1% so far this year. Estimates for its 2025 earnings per share have increased from $1.32 to $1.37 over the past 60 days, while those for 2026 have increased from $1.36 per share to $1.44 per share.
Zacks Names #1 Semiconductor Stock
This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Sanofi Q3 Earnings Beat, Dupixent Drives Growth as Vaccines Decline

(RTTNews) - French drug major Sanofi (SNY) reported Friday slightly lower profit in its third quarter, even as net sales were higher, benefited mainly by strong growth in Dupixent, which for the first time reached above 4 billion euros sales in a quarter.
Looking ahead, for fiscal 2025, the company continues to expect sales to grow by a high single-digit percentage at constant exchange rates. Sanofi confirmed the expectation of a strong business earnings per share rebound with growth at a low double-digit percentage at CER, before share buyback.
Paul Hudson, Chief Executive Officer, said, "Sanofi will strategically deploy capital towards growth and differentiated science with expected attractive financial returns. As we are looking forward to 2026, we are confident in our ability to pursue our current trajectory of profitable growth."
In the third quarter, the company's net income attributable to equity holders dropped to 2.80 billion euros from 2.82 billion euros last year. Basic earnings per share, however, grew to 2.30 euros from 2.25 euros a year ago on lower share count.
Basic earnings per share from continuing operations were 2.32 euros, higher than 2.22 euros last year.
Business net income was 3.55 billion euros, an increase of 4 percent from 3.41 billion euros a year ago. Business earnings per share improved to 2.91 euros from 2.72 euros last year.
In the quarter, research and Development expenses dropped 4.9 percent and selling, general and administrative expenses grew 7.1 percent to support launches.
Net sales increased 2.3 percent to 12.43 billion euros from 12.16 billion euros last year. Net sales grew 7 percent at constant exchange rates.
Dupixent sales climbed 26.2 percent from last year to 4.2 billion euros. Meanwhile, vaccines sales decreased 7.8 percent from last year to 3.4 billion euros, from lower influenza sales.
Pharma launches increased sales by 57.1 percent, reaching 1.0 billion euros, driven by ALTUVIIIO and Ayvakit.
Sanofi added that it intends to complete its 5 billion euros share buyback program in 2025, of which 86.1 percent has been executed to date.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Sanofi Q3 Profit Edges Down, Net Sales Rise; Confirms FY25 View, Sees Profitable Growth In FY26

The following companies are expected to report earnings prior to market open on 10/24/2025. Visit our Earnings Calendar for a full list of expected earnings releases.
Procter & Gamble Company (PG)is reporting for the quarter ending September 30, 2025. The consumer company's consensus earnings per share forecast from the 9 analysts that follow the stock is $1.90. This value represents a 1.55% decrease compared to the same quarter last year. In the past year PG has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2026 Price to Earnings ratio for PG is 21.81 vs. an industry ratio of 22.60.
Sanofi (SNY)is reporting for the quarter ending September 30, 2025. The large cap pharmaceutical company's consensus earnings per share forecast from the 5 analysts that follow the stock is $1.60. This value represents a 1.91% increase compared to the same quarter last year. Zacks Investment Research reports that the 2025 Price to Earnings ratio for SNY is 11.13 vs. an industry ratio of 14.80.
HCA Healthcare, Inc. (HCA)is reporting for the quarter ending September 30, 2025. The medical services company's consensus earnings per share forecast from the 10 analysts that follow the stock is $5.65. This value represents a 11.88% increase compared to the same quarter last year. In the past year HCA has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 10.5%. Zacks Investment Research reports that the 2025 Price to Earnings ratio for HCA is 16.86 vs. an industry ratio of 2.60, implying that they will have a higher earnings growth than their competitors in the same industry.
General Dynamics Corporation (GD)is reporting for the quarter ending September 30, 2025. The aerospace and defense company's consensus earnings per share forecast from the 8 analysts that follow the stock is $3.73. This value represents a 11.34% increase compared to the same quarter last year. GD missed the consensus earnings per share in the 3rd calendar quarter of 2024 by -5.37%. Zacks Investment Research reports that the 2025 Price to Earnings ratio for GD is 22.19 vs. an industry ratio of 5.40, implying that they will have a higher earnings growth than their competitors in the same industry.
Illinois Tool Works Inc. (ITW)is reporting for the quarter ending September 30, 2025. The machinery company's consensus earnings per share forecast from the 6 analysts that follow the stock is $2.69. This value represents a 1.51% increase compared to the same quarter last year. In the past year ITW has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 0.78%. Zacks Investment Research reports that the 2025 Price to Earnings ratio for ITW is 24.37 vs. an industry ratio of 16.20, implying that they will have a higher earnings growth than their competitors in the same industry.
Booz Allen Hamilton Holding Corporation (BAH)is reporting for the quarter ending September 30, 2025. The consulting company's consensus earnings per share forecast from the 8 analysts that follow the stock is $1.49. This value represents a 17.68% decrease compared to the same quarter last year. In the past year BAH has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 1.37%. Zacks Investment Research reports that the 2026 Price to Earnings ratio for BAH is 15.60 vs. an industry ratio of 24.20.
Gentex Corporation (GNTX)is reporting for the quarter ending September 30, 2025. The auto (truck) company's consensus earnings per share forecast from the 3 analysts that follow the stock is $0.47. This value represents a 11.32% decrease compared to the same quarter last year. GNTX missed the consensus earnings per share in the 4th calendar quarter of 2024 by -20.41%. Zacks Investment Research reports that the 2025 Price to Earnings ratio for GNTX is 14.64 vs. an industry ratio of 13.20, implying that they will have a higher earnings growth than their competitors in the same industry.
Flagstar Bank, N.A. (FLG)is reporting for the quarter ending September 30, 2025. The bank (northeast) company's consensus earnings per share forecast from the 10 analysts that follow the stock is $-0.06. This value represents a 91.30% increase compared to the same quarter last year. Zacks Investment Research reports that the 2025 Price to Earnings ratio for FLG is -29.49 vs. an industry ratio of 12.00.
First Hawaiian, Inc. (FHB)is reporting for the quarter ending September 30, 2025. The bank (west) company's consensus earnings per share forecast from the 5 analysts that follow the stock is $0.52. This value represents a 8.33% increase compared to the same quarter last year. In the past year FHB has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 18.37%. Zacks Investment Research reports that the 2025 Price to Earnings ratio for FHB is 11.51 vs. an industry ratio of 7.90, implying that they will have a higher earnings growth than their competitors in the same industry.
Coca Cola Femsa S.A.B. de C.V. (KOF)is reporting for the quarter ending September 30, 2025. The beverages company's consensus earnings per share forecast from the 1 analyst that follows the stock is $1.35. This value represents a 8.78% decrease compared to the same quarter last year. KOF missed the consensus earnings per share in the 2nd calendar quarter of 2025 by -14.47%. Zacks Investment Research reports that the 2025 Price to Earnings ratio for KOF is 14.12 vs. an industry ratio of -2.00, implying that they will have a higher earnings growth than their competitors in the same industry.
Stellar Bancorp, Inc. (STEL)is reporting for the quarter ending September 30, 2025. The banks (southeast) company's consensus earnings per share forecast from the 3 analysts that follow the stock is $0.50. This value represents a 20.63% decrease compared to the same quarter last year. In the past year STEL has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 13.33%. Zacks Investment Research reports that the 2025 Price to Earnings ratio for STEL is 15.27 vs. an industry ratio of 9.90, implying that they will have a higher earnings growth than their competitors in the same industry.
Virtus Investment Partners, Inc. (VRTS)is reporting for the quarter ending September 30, 2025. The finance/investment management company's consensus earnings per share forecast from the 3 analysts that follow the stock is $6.71. This value represents a 3.03% decrease compared to the same quarter last year. In the past year VRTS has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 0.64%. Zacks Investment Research reports that the 2025 Price to Earnings ratio for VRTS is 6.96 vs. an industry ratio of 13.20.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Pre-Market Earnings Report for October 24, 2025 : PG, SNY, HCA, GD, ITW, BAH, GNTX, FLG, FHB, KOF, STEL, VRTS

(RTTNews) - Sanofi (SNY, SNYNF, SAN.PA) announced positive topline results from the global Phase 2 ElevAATe study evaluating efdoralprin alfa (SAR447537, formerly INBRX-101) in adults with alpha-1 antitrypsin deficiency (AATD) emphysema. The investigational recombinant human AAT-Fc fusion protein met all primary and key secondary endpoints when administered every three weeks (Q3W) or four weeks (Q4W).
Efdoralprin alfa demonstrated a statistically significant greater mean increase in functional AAT (fAAT) levels within the normal range, as measured by trough concentrations at steady state, compared to weekly plasma-derived augmentation therapy at week 32 (p0.0001). Key secondary endpoints were also met, including superior mean fAAT average concentration and a higher percentage of days above the lower limit of the normal range for both dosing regimens.
The therapy was well tolerated, with an adverse event profile comparable to plasma-derived therapy. Additional safety data will be collected in the ongoing ElevAATe OLE Phase 2 extension study.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Sanofi's Efdoralprin Alfa Meets All Endpoints In Phase 2 AATD Emphysema Study

(RTTNews) - Sanofi (SNY) said the FDA has accepted for expedited review the supplemental biologics license application for Tzield to delay the progression of stage 3 type 1 diabetes in adults and pediatric patients eight years of age and older recently diagnosed with stage 3 T1D. The sBLA is supported by the results from the PROTECT phase 3 study.
The company noted that FDA nominated Tzield for the Commissioner's National Priority Voucher pilot program based on its potential to address a large unmet medical need. The CNPV program aims to shorten the review process to 1-2 months.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Sanofi: FDA Accepts SBLA For Tzield For Expedited Review

(RTTNews) - Sanofi SA (SNY) announced that new data from the FLUNITY-HD study showed its high-dose influenza vaccine significantly reduces the risk of hospitalization in adults aged 65 and older compared to standard-dose flu vaccines.
Compared to standard-dose influenza vaccines, Efluelda (also known as Fluzone High-Dose) demonstrated an additional 31.9% reduction in laboratory-confirmed influenza-related hospitalizations in adults 65 years and older.
The findings come from FLUNITY-HD, the largest influenza vaccine effectiveness study conducted in individually randomized older adults. The study included nearly half a million participants across multiple flu seasons and two distinct geographic regions.
Beyond influenza-related hospitalizations, Efluelda/Fluzone High-Dose also provided superior protection against hospitalizations due to pneumonia or influenza, cardio-respiratory events, and all-cause hospitalizations in older adults when compared to standard-dose influenza vaccines.
With the addition of these new data, our high-dose influenza vaccine is now supported by 15 years of clinical evidence, encompassing over 45 million older adults.
Efluelda/Fluzone High-Dose is the first vaccine to demonstrate superior protection against both influenza infection and related hospitalizations in individually randomized studies involving adults aged 65 and older, Sanofi said.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Sanofi Reports Superior Protection For Older Adults With High-Dose Influenza Vaccine

Merck MRK is facing persistent challenges for its second-largest product, Gardasil, which is a vaccine for the prevention of certain cancers caused by human papillomavirus. Though the vaccine’s sales rose consistently till 2022, it started witnessing sluggish sales from 2024.
During the first half of 2025, Gardasil sales declined 48% on a year-over-year basis to $2.45 billion. Sales of Gardasil are declining due to weak performance in China, which resulted from sluggish demand trends amid an economic slowdown. Lower demand in China resulted in above-normal channel inventory levels at Merck’s commercialization partner in China, Zhifei.
Accordingly, Merck decided to temporarily halt shipments of Gardasil in China to allow Zhifei to burn down existing inventory. Merck does not expect to resume shipments to China through at least the end of 2025.
Gardasil sales are expected to decline significantly in 2025 from 2024 levels.
Merck is also seeing lower demand for Gardasil in Japan. Management expects Gardasil sales to remain weak in China as well as Japan in the third and fourth quarters of 2025. Our estimates for Gardasil sales suggest a negative CAGR of 15.1% over the next three years.
MRK's Other Vaccines & Competition in the Target Market
Besides Gardasil, Merck markets other vaccines like ProQuad/ M-M-R II/Varivax (measles, mumps, rubella and varicella virus vaccine, Vaxneuvance (pneumococcal 15-valent conjugate vaccine), RotaTeq (rotavirus vaccine), Pneumovax 23 (pneumococcal vaccine polyvalent) and its newest jab, Capvaxive (21-valent pneumococcal conjugate vaccine).
Sales of other vaccines like Proquad, M-M-R II, Varivax, Rotateq and Pneumovax 23 also declined during the first half of 2025.
Merck’s newest respiratory syncytial virus (RSV) antibody, Enflonsia (clesrovimab), was approved in the United States in June 2025, while it is under review in the EU. Merck is currently gearing up to launch Enflonsia to help protect infants entering their first RSV season.
Per management, Enflonsia is the first and only treatment option designed to protect infants with the same dose regardless of weight.
However, Enflonsia is likely to face stiff competition from AstraZeneca AZN/Sanofi’s SNY RSV antibody Beyfortus, which was approved for a similar indication in 2023.
AstraZeneca records a 50% share of gross profits on sales of Beyfortus in major markets outside the United States and 25% of brand revenues in the rest of the world markets received from partner Sanofi as Alliance revenues.
Beyfortus achieved blockbuster status in its first full year of sales in 2024.
Besides antibodies, some vaccines have been approved for preventing RSV in certain patients in the United States. These include Pfizer’s Abrysvo, GSK’s Arexvy and Moderna’s mRESVIA.
MRK's Price Performance, Valuation and Estimates
Year to date, shares of Merck have declined 15.8% against the industry’s rise of 5.6%. The stock has also underperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, Merck appears attractive relative to the industry. Going by the price/earnings ratio, the company’s shares currently trade at 8.97 forward earnings, lower than 15.62 for the industry and its 5-year mean of 12.64.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings per share has decreased from $8.94 per share to $8.92, while the same for 2026 has decreased from $9.55 to $9.44 over the past 60 days.
Image Source: Zacks Investment Research
MRK's Zacks Rank
Merck currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Indicator	TTM Median
P/E	18.67 23.75
Price/Sales	2.68 3.01
P/B	1.51 2.20
P/FCF	19.98 18.30

Indicator	TTM Median
ROE	11.20 25.41
ROA	6.40 6.00
ROI	9.66 9.66
Net Worth	124.55 0.20
Quick Ratio	0.69 1.71
Current Ratio	1.37 2.83

Indicator	TTM Median
Net Profit Margin	14.37 10.25
Operating Margin	19.42 14.24
Gross Margin	71.08 68.59
Return on tangible equity	135.36 53.53

Indicator	TTM Median
Revenue	11.17B 16.00M
Gross Profit	8.13B —
EBITDA	2.44B —

Sanofi

TTM metrics for the latest quarter under IFRS and their historical dynamics

Valuation

Debts

Efficiency

Other ratios

Revenue